.png){kind=icon}
CarciReagent is an in vitro diagnostic self-test designed for the early detection of serious diseases by identifying elevated levels of monohydroxyphenol metabolites, particularly tyrosine, in urine.
Elevated tyrosine levels can be indicative of certain malignancies, making this test a valuable tool for early cancer detection. By providing rapid, indicative results, CarciReagent enables individuals to seek timely medical consultation, facilitating prompt and informed healthcare decisions
You can easily complete the test at home on your own without any prior preparation.
With one test you can detect minimum of 20 serious diseases, from inflamamtion to most danger – many times of malignant tumors
High sensitivity for malignant tumors (96.7%) and specificity in healthy individuals (99.4%).
High sensitivity for malignant tumors (96.7%) and specificity in healthy individuals (99.4%).
Customer Testimonials
“The cancer detection product from CarciReagent has significantly impacted the way we diagnose and treat cancer. It's a game-changer in the medical field.”
Dr. Sarah Johnson
“I have been thoroughly impressed by the accuracy and convenience of CarciReagent's cancer detection solution. It has made a remarkable difference in our clinical practice.”
Dr. Michael Lee
“CarciReagent's cancer detection technology has proven to be invaluable in our efforts to detect cancer at its early stages, leading to improved patient outcomes.”
Dr. Emily Rodriguez
“Firstly I was a little bit nervous about what color I will get, but it turned to be bright yellow, was so happy to see that. Even my GP grabbed one later on for himself.”
Paul Clove
The Carci Reagent is a diagnostic product that can detect several types of cancers, particularly in early stages.
It is designed to be used in conjunction with laboratory tests and diagnostic imaging to help identify abnormal cellular activity. According to its specifications, the reagent is primarily used to assist in identifying cancers such as:
Breast cancer | Lung cancer
Colon cancer | Prostate cancer
Liver cancer | Stomach cancer
It is often applied in cytology and histology to detect cellular abnormalities that may indicate the presence of malignant tumors.
Cancer rates in New Zealand are high, especially for lung, breast, prostate, and colorectal cancers. Lung and colorectal cancers remain leading causes of death, though lung cancer rates are decreasing with reduced smoking. Continued efforts in early detection and targeted screening are essential to improve cancer outcomes nationwide
Prostate
4000 p/y
Colon, rectal
1850 p/y
Lung
1660 p/y
Breast
3450 p/y
Breast
1715 p/y
